Australia markets closed

Innoviva Inc (HVE.BE)

Berlin - Berlin Delayed price. Currency in EUR
Add to watchlist
13.90-0.10 (-0.71%)
As of 08:08AM CET. Market open.
Full screen
Previous close14.00
Open14.00
Bid14.00 x 0
Ask14.20 x 0
Day's range13.90 - 13.90
52-week range9.95 - 15.30
Volume80
Avg. volume0
Market capN/A
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress

    BURLINGAME, Calif., February 29, 2024--Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today reported financial results for the fourth quarter and full year ended December 31, 2023 and highlighted select corporate achievements.

  • Business Wire

    Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress

    BURLINGAME, Calif., November 01, 2023--Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified holding company with a portfolio of royalties and other healthcare assets, today reported financial results for the third quarter ended September 30, 2023, highlighted select corporate achievements and provided an overview of its key business initiatives.

  • Business Wire

    Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea

    GENEVA & WALTHAM, Mass., November 01, 2023--The Global Antibiotic Research & Development Partnership (GARDP), in collaboration with Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (Nasdaq: INVA), announced today that zoliflodacin, a first-in-class antibiotic, met its primary endpoint in an unprecedented global pivotal Phase 3 clinical trial. Study investigators found that oral zoliflodacin demonstrated statistical non-inferiority of microbiological cure at the urogenital site whe